I'm hoping they go with 'non-exclusivity' and licence it out, then all 'players' can improve their 'products' for the 'greater good' of patients,as it seems pretty apparent across the 'range' of cancers out there, that different patients tend to respond to different treatments/drugs, at different stages of disease...
If CAVATAK can improve those 'patient outcomes' across a wider market, everyone (including us as SHs) win...
It would essentially mean that as new 'treatments' come through the 'pre-clinical/clinical' stages, they could open the 'combo box' with VLA to see if the 'combo' adds significant value...
Just some food for thought, 8 years and holding on tightly..!!
ML
I'm hoping they go with 'non-exclusivity' and licence it out,...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)